TY - JOUR
T1 - Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
AU - Zaja, Francesco
AU - Battista, Marta Lisa
AU - Pirrotta, Maria Teresa
AU - Palmieri, Salvatore
AU - Montagna, Michela
AU - Vianelli, Nicola
AU - Marin, Luciana
AU - Cavallin, Margherita
AU - Bocchia, Monica
AU - Defina, Marzia
AU - Ippoliti, Micaela
AU - Ferrara, Felicetto
AU - Patriarca, Francesca
AU - Avanzini, Maria Antonietta
AU - Regazzi, Mario
AU - Baccarani, Michele
AU - Isola, Miriam
AU - Soldano, Franca
AU - Fanin, Renato
PY - 2008/6
Y1 - 2008/6
N2 - Rituximab 375 mg/m2 weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50×10 9/L) and complete responses (platelet count > 100×10 9/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose.
AB - Rituximab 375 mg/m2 weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50×10 9/L) and complete responses (platelet count > 100×10 9/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose.
KW - B-cell depletion
KW - Immune thrombocytopenia
KW - Lower dose rituximab
UR - http://www.scopus.com/inward/record.url?scp=44949126978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44949126978&partnerID=8YFLogxK
U2 - 10.3324/haematol.12206
DO - 10.3324/haematol.12206
M3 - Article
C2 - 18403395
AN - SCOPUS:44949126978
VL - 93
SP - 930
EP - 933
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 6
ER -